TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ARID1A drug discovery and synthetic lethality screening. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | ARID1A ARID Domain Recombinant Protein (HEK293 expressed) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. |
View ARID1A Products |
| Antigen (Mutant) | ARID1A R1989* / Q1926* Truncation Mutants Common cancer loss-of-function variants. Theoretical MW verified. |
View ARID1A Products |
| Gene Delivery | ARID1A sgRNA / Lentivirus KO Particles & Promise-ORF Lentivirus For stable knockout/knockdown and rescue experiments. |
View ARID1A Products |
| Benchmark Ab | Anti-ARID1A Benchmark Antibody Recombinant positive control for IHC/WB (sequence of clinical diagnostic clones). |
View ARID1A Products |
| Validator | ARID1A siRNA Set For transient knockdown verification in synthetic lethal assays. |
View ARID1A Products |
| Synthetic Lethality Partner A | EZH2 Histone methyltransferase; PRC2 complex catalytic subunit. Primary synthetic lethality partner. |
View EZH2 Products |
| Synthetic Lethality Partner B | ARID1B Critical paralog dependency in ARID1A-deficient cancers. |
View ARID1B Products |
| Synthetic Lethality Partner C | ATR DNA damage response kinase; vulnerability target for ARID1A-mutant cancers. |
View ATR Products |
| Pathway Associate | SMARCB1 (INI1) Core SWI/SNF complex subunit; frequently co-mutated. |
View SMARCB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Generating robust ARID1A-deficient tumor models | Sequence Verified Lentivirus for stable knockout/knockdown, essential for synthetic lethality screening. |
| Validating SWI/SNF complex PPI & domain mapping | High Purity (>95%) recombinant ARID1A domain truncations (ARID, HSA, C-terminal) with Mass Spec confirmation. |
| Modeling loss-of-function mutations | R1989* and Q1926* premature termination variants; High Purity for binding studies; Mutant vs WT selectivity panels. |
| Cross-species ortholog evaluation for tox | Human / Mouse / Cyno ARID1A recombinant domain proteins available. |
| High background in target validation | Validated ARID1A siRNA sets for orthogonal specificity checks in cell-based assays. |
Live ARID1A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic strategy for ARID1A-mutant cancers has shifted entirely from direct inhibition to synthetic lethality exploitation. As ARID1A is a tumor suppressor frequently lost in ovarian clear cell carcinoma, endometrial cancers, and gastric cancers, current R&D focuses on vulnerabilities in ARID1A-deficient tumors. Clinical-stage efforts target EZH2 (e.g., tazemetostat by Ipsen/Epizyme), ATR, and PARP inhibitors. The next wave of development includes targeted protein degradation (PROTACs) against ARID1B, molecular glues modulating SWI/SNF complex, and biomarker-driven patient stratification using ARID1A IHC loss-of-function detection.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need |
|---|---|---|---|
| Synthetic Lethality (EZH2/ATR/PARP inhibitors) | Epizyme (Ipsen), AstraZeneca, Merck KGaA, BMS | Ovarian Clear Cell, Endometrial, Gastric Carcinoma | Isogenic cell lines (ARID1A KO/mutant) for sensitivity screening |
| Targeted Protein Degrader (PROTAC) / Molecular Glue | Foghorn Therapeutics, Prelude, Arvinas, Cullgen | ARID1A-deficient Solid Tumors | PPI assays using purified ARID1A domains; selectivity against ARID1B |
| Biomarker Diagnostic / IHC | Roche Diagnostics, Agilent | Pan-cancer screening (Gastric, Colorectal) | Loss-of-function detection using high-specificity Anti-ARID1A benchmark Abs |
| Direct Epigenetic Regulator (Preclinical) | Early-stage biotech / Academia | Pan-tumor (ARID1A-mutant) | DNA-binding assays (AT-rich motif) using high-purity ARID domain protein |